Literature DB >> 28157676

Inhibitory antibodies against factor VIII C1 domain.

Gary E Gilbert1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 28157676      PMCID： PMC5073179          DOI： 10.1182/blood-2016-08-727818

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa.

Authors:  P J Fay; D Scandella
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

2.  The principal results of the International Immune Tolerance Study: a randomized dose comparison.

Authors:  Charles R M Hay; Donna M DiMichele
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

3.  Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.

Authors:  Esther Bloem; Maartje van den Biggelaar; Aleksandra Wroblewska; Jan Voorberg; Johan H Faber; Marianne Kjalke; Henning R Stennicke; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-09-05       Impact factor: 5.157

4.  Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry.

Authors:  Francesco Baudo; Peter Collins; Angela Huth-Kühne; Hervé Lévesque; Pascual Marco; László Nemes; Fabio Pellegrini; Lilian Tengborn; Paul Knoebl
Journal:  Blood       Date:  2012-05-22       Impact factor: 22.113

5.  Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine.

Authors:  Gary E Gilbert; Valerie A Novakovic; Jialan Shi; Jan Rasmussen; Steven W Pipe
Journal:  Blood       Date:  2015-07-10       Impact factor: 22.113

6.  Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans.

Authors:  Christoph J Hofbauer; Shawn F J Whelan; Maria Hirschler; Peter Allacher; Frank M Horling; John-Philip Lawo; Johannes Oldenburg; Andreas Tiede; Christoph Male; Jerzy Windyga; Andreas Greinacher; Paul N Knöbl; Gerald Schrenk; Jadranka Koehn; Friedrich Scheiflinger; Birgit M Reipert
Journal:  Blood       Date:  2014-12-16       Impact factor: 22.113

7.  Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice.

Authors:  M Dewerchin; L Van der Elst; I Singh; S Grailly; J-M Saint-Remy; D Collen; M Jacquemin
Journal:  J Thromb Haemost       Date:  2004-01       Impact factor: 5.824

8.  High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

Authors:  Glaivy Batsuli; Wei Deng; John F Healey; Ernest T Parker; W Hunter Baldwin; Courtney Cox; Brenda Nguyen; Joerg Kahle; Christoph Königs; Renhao Li; Pete Lollar; Shannon L Meeks
Journal:  Blood       Date:  2016-07-05       Impact factor: 22.113

9.  Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.

Authors:  Shannon L Meeks; John F Healey; Ernest T Parker; Rachel T Barrow; Pete Lollar
Journal:  Blood       Date:  2007-09-11       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.